Genentech — Merger or Acquisition (November 2006)
19 slides from Genentech's merger presentation, Nov 17, 2006
Slide 1: Schedule 14A Soliciting Material
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confid
Slide 2: Genentech: An Overview
Genentech: An Overview Patrick Yang, Executive Vice President Manufacturing, Genentech November 17, 2006 #1
Slide 3: Meeting Agenda
Meeting Agenda Introduction to Genentech Pat Yang Manufacturing Next steps Pat Yang Q&A All #2
Slide 4: Manufacturing
Manufacturing • Genentech is a world leader in biotech manufacturing, with more FDA-approved manufacturing capacity for the production of biotech medicines than any other company • Four facilities: South San Francisco, CA; Vacaville, CA and Oceanside, CA and Porriño, Spain • We believe we have the r
Slide 5: Near-term Key Capacity Enhancement Projects
Near-term Key Capacity Enhancement Projects Facility Enhancement Project Status Oceanside, CA • Anticipate FDA licensure to produce NIMO commercial Avastin in 1H’07 (90,000 liters) Genentech Bulk Manufacturing • Anticipate construction, qualification and Vacaville, CA licensure of our new plant in V
Slide 6: 2006 Key Contract Manufacturing Accomplishments
2006 Key Contract Manufacturing Accomplishments • Our strategies include expanding or acquiring facilities and engaging contract manufacturers that produce Genentech’s products on our behalf Novartis • Began manufacturing all future worldwide Pharmaceuticals supply of Xolair Huningue, France Wyeth B
Slide 7: Other 2006 Manufacturing Accomplishments
Other 2006 Manufacturing Accomplishments • Completed qualification runs of Avastin at Oceanside • Expect FDA licensure to produce Avastin 1H’07 • Purchased state-of-the-art finish/fill facility in Hillsboro, Oregon • Expect facility to be licensed and operational in 2010 • Expect FDA approval of hig
Slide 8: Genentech's Oceanside Facilities
Genentech’s Oceanside Facilities NIMO NICO Manufacturing Facility Commercial Facility Clinical Facility Purchased June 2005 February 2006 Potential Capacity 90,000 liters 5,500 liters Approximately 530 employees as Plan to employ approximately 30 # of Employees of September 30, 2006 employees by the
Slide 9: Manufacturing Capacity
Manufacturing Capacity Genentech Bulk Manufacturing Facility Current Capacity Comments •First licensed in 1985. Licensed to produce Activase, Avastin, Cathflo Activase, Herceptin, South San Francisco, CA 96,000 (8x12,000L) Lucentis, Nutropin, Nutropin AQ, Pulmozyme, Raptiva, Rituxan, and TNKase. Vac
Slide 10: Genentech Commercial Cell Culture Bioreactor Capacity
Genentech Commercial Cell Culture* Bioreactor Capacity 650,000 600,000 550,000 500,000 450,000 400,000 350,000 Current Commercial Capacity 300,000 South San Francisco, CA and Vacaville, CA (CCP1) 250,000 200,000 150,000 100,000 50,000 0 1999 2000 2001 2002 2003 2004 2005 2006 1H'07 2008 2H'09 2010 *
Slide 11: What Does This Mean For You?
What Does This Mean For You? • We encourage continued focus on your current efforts to bring important new medicines to patients, as this is in everyone’s best interest • While we fully expect the deal to go through, we aren’t there yet • Your current management continues to run the company until cl
Slide 12: Transition Process Will Be Organized Around Four Areas
Transition Transition Process Process Will Will Be Be Organized Organized Around Around Four Four Areas Areas Process Summary HR Facilities/ R&D Change Contracts Property Programs management Number of 1. Number, location, Number and Number of contracts; Rights Assessmen and capability of value of R&
Slide 13: Decisions Yet to be Determined
Decisions Yet to be Determined • Future plans for Tanox’s pipeline • Future plans for Tanox’s sites • Future status of employees • Who will be retained • How/when decisions will be made after close; however, our intent is for decisions to be made as quickly and with as much transparency as possible
Slide 14: Next Steps
Next Steps •Today: • Small functional meetings with Genentech and Tanox management •Next few months: • Additional site visits to establish post-close integration plans • Deal not closed until at least Q1’07; Tanox remains an independent company until the deal closes. It is important to stay focused
Slide 15: Genentech Transition Team
Genentech Transition Team Facilities/ Communi Contracts R&D HR Property cation Mark Asbury Andy Chan Leigh Morgan Charles Calderaro Ashraf Hanna, Neil Cohen Team Leader Sean Bohen Brian Muma Ray Sanchez- Pescadore, Project Manager #14
Slide 16: Forward Looking Statement
Forward Looking Statement • This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, our expectations regarding the closing of the acquisition and the integration of
Slide 17: Thank You
Thank You #16
Slide 18: Q&A Session
Q&A Session #17
Slide 19: Forward-looking statements notice
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, our expectations regarding the closing of the acquisition and the integration of the operations of Tanox, ou